Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SON-1010 |
Synonyms | |
Therapy Description |
SON-1010 is a recombinant variant of IL-12 linked to an albumin-binding domain, which potentially induces enhanced antitumor immune response (Cancer Res (2023) 83 (8_Supplement): CT245). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SON-1010 | SON 1010|SON1010 | SON-1010 is a recombinant variant of IL-12 linked to an albumin-binding domain, which potentially induces enhanced antitumor immune response (Cancer Res (2023) 83 (8_Supplement): CT245). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05352750 | Phase I | SON-1010 | Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05756907 | Phase Ib/II | Atezolizumab + SON-1010 SON-1010 | Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer | Recruiting | USA | AUS | 0 |